What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
關於ionis pharmaceuticals有14個分析師評級意見
The standing of...14 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月內，有14位分析師分享了他們對Ionis Pharmaceuticals (NASDAQ:IONS)的評價，表達了看好和看淡的不同觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了分析師們最近的評級，揭示了過去30天內情緒的變化並將其與前幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $59.79, a high estimate of $75.00, and a low estimate of $37.00. This upward trend is apparent, with the current average reflecting a 10.72% increase from the previous average price target of $54.00.
正面營業收入趨勢：檢視Ionis Pharmaceuticals在3個月內的財務情況，揭示了一個正面的故事。截至2024年6月30日，公司實現了19.55%的營業收入增長率，展示了頂線收益的大幅增加。與同行相比，該公司的增長率低於健康醫療領域同行的平均水平。
Diving into Analyst Ratings: An In-Depth Exploration
深入探討分析師評級：分析師評級的深度探討
The standing of...
資產回...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。